Last week during the EWGGD in Clermont-Ferrand, our CEO Tanya Collin-Histed presented the poster on the IGA's global disease registry for neuronopathic Gaucher disease.
Working in partnership with Aparito, the IGA acted as a lead instigator, bringing together all the partners with funding from pharmaceutical partners to explore patient, KOL and pharma needs and requirements.
Phase 1 has now been completed and we will be bringing news about the next steps soon so watch this space!
Donation
Join us
Newsletter Subscription